Mass General Brigham researchers found that the intensive cholesterol-lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high-risk patients who did not have known ...
MedPage Today on MSN
PCSK9 Drug Prevents First Heart Events in Diabetes Patients Without Atherosclerosis
VESALIUS-CV further extends PCSK9 inhibitor's primary prevention benefits ...
In high-risk patients with diabetes but without known atherosclerosis, evolocumab reduced risk for a first major CV event compared with placebo, according to a subgroup analysis of the VESALIUS-CV ...
Earlier use of cholesterol lowring drug evolocumab may reduce heart attack and stroke risk in high-risk diabetes patients without known heart disease.
OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision ...
HELSINKI, 12 March 2026 - Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory ...
Q4 2025 Earnings Call March 24, 2026 4:30 PM EDTCompany ParticipantsMiranda Benvenuti - Investor Relations ExecutivePeter Altman ...
Aplagon doses first patient in phase 2a trial of APAC with peripheral arterial occlusive disease/chronic limb threatening ischemia: Helsinki, Finland Saturday, March 14, 2026, 18: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results